Ketoconazole vs. abiraterone acetate in mCRPC? Never gonna happen!

In a commentary in this week’s New England Journal of Medicine, Mailankody and Prasad use abiraterone acetate vs. ketoconazole in the treatment of metastatic, castration-resistant prostate cancer (mCRPC) as an example of the type of comparative effectiveness trial that should — but probably never will — be done. … READ MORE …

Regulators suspend marketing of oral ketoconazole in Europe

On Friday last week, US regulators recommended that oral ketoconazole should no longer be used as a first-line treatment for fungal infections whereas European regulators recommended a complete suspension of marketing for all oral ketoconazole-containing drugs. … READ MORE …

Effects of ketoconazole, abiraterone, and chemotherapy in men with CRPC

Studies to be presented at the ASCO meeting next week suggest that: (a) high-dose ketoconazole has very limited activity in the treatment of men who have already been treated with abiraterone acetate; (b) men treated with either high-dose ketoconazole or abiraterone acetate (or both) can still respond to docetaxel-based chemotherapy. … READ MORE …

Acid-suppressive therapy + ketoconazole in men with CRPC

Ketoconazole has long been used as a “third-line” agent in men with castration-resistant prostate cancer (CRPC) who have progressive disease after standard forms of hormonal therapy. For some patients, ketoconazole can be clinically effective and cost-effective compared to other clinical options. … READ MORE …

Older (and newer) drugs in the management of CRPC

On his Advanced Prostate Cancer blog site, Joel Nowak has just published a series of five brief articles on the opportunities offered by some older agents that are available for use as second-line therapies in the management of patients who have a rising PSA after treatment with standard forms of androgen deprivation therapy (ADT). … READ MORE …

High-dose ketoconazole + docetaxel for treatment of CRPC?

Docetaxel + prednisone is the current standard treatment for men with castration-resistant prostate cancer (CRPC). However, the survival benefit of this form of treatment is small compared to older forms of therapy. … READ MORE …

More evidence for ketoconazole + dutasteride in CRPC

The evidence supporting a role for the combination of dutasteride with ketoconazole as a form of second- or third-line hormone therapy for patients with castration-resistant prostate cancer (CRPC) appears to be increasing. … READ MORE …

Non-ASTRO prostate cancer news reports: Friday, November 6, 2009

In today’s news reports from sources other than the ASTRO meeting, we note items dealing with:

  • PSA bounce in brachytherapy patients
  • Fatal prostate cancer and a history of smoking
  • Ketoconazole + dutasteride in treatment of CRPC … READ MORE …